Exelixis
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1994-01-01
- Employees
- 1.3K
- Market Cap
- $7.3B
- Website
- http://www.exelixis.com
- Introduction
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer
Phase 2
Terminated
- Conditions
- Prostate CancerCastration Resistant Prostate CancerProstatic Neoplasms
- Interventions
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2015-02-20
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 54
- Registration Number
- NCT01995058
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Phase 3
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: Placebo tablets
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 707
- Registration Number
- NCT01908426
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
Phase 4
Active, not recruiting
- Conditions
- Medullary Thyroid Cancer
- Interventions
- Drug: Placebo tabletDrug: Placebo capsule
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 247
- Registration Number
- NCT01896479
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Phase 3
Completed
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2013-05-31
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 658
- Registration Number
- NCT01865747
A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 32
- Registration Number
- NCT01761773
Expanded Access of Cabozantinib in Medullary Thyroid Cancer
- Conditions
- Medullary Thyroid Cancer
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Exelixis
- Registration Number
- NCT01683110
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Phase 3
Completed
- Conditions
- PainProstate CancerCastration Resistant Prostate CancerProstatic Neoplasms
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 1028
- Registration Number
- NCT01605227
Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
Phase 1
Completed
- Conditions
- Solid TumorsCancerNSCLC
- Interventions
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 85
- Registration Number
- NCT01553656
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇯🇵The Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Ariake, Koto, Japan
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Phase 3
Terminated
- Conditions
- Prostatic NeoplasmsCastration Resistant Prostate CancerPainProstate Cancer
- Interventions
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 119
- Registration Number
- NCT01522443
Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 26
- Registration Number
- NCT01493869
- Locations
- 🇺🇸
McGuire VA Medical Center, Richmond, Virginia, United States
© Copyright 2025. All Rights Reserved by MedPath